drugset / Trial / NCT02884713
Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia
NaSingle-groupOpen-labelTreatment
Summary
Helicobacter pylori (H. pylori) eradication is achieved in 60-80% with first-line therapy. Different second-line therapeutic options are available. However, the success of second-line therapy has not been addressed or reported from Saudi Arabia. Objectives The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment.
Timeline
- Start
- 2013-06
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 100 mg | — |
| Subject | Esomeprazole | Small molecule | 20 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |